UnitedHealth Group (UNH)
(Delayed Data from NYSE)
$501.13 USD
+7.95 (1.61%)
Updated Apr 19, 2024 04:00 PM ET
After-Market: $499.20 -1.93 (-0.39%) 7:54 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
UnitedHealth Group (UNH) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$574.29 | $675.00 | $460.00 | 16.45% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for UnitedHealth Group comes to $574.29. The forecasts range from a low of $460.00 to a high of $675.00. The average price target represents an increase of 16.45% from the last closing price of $493.18.
Analyst Price Targets (21)
Broker Rating
UnitedHealth Group currently has an average brokerage recommendation (ABR) of 1.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 22 brokerage firms. The current ABR compares to an ABR of 1.30 a month ago based on 22 recommendations.
Of the 22 recommendations deriving the current ABR, 18 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 81.82% and 9.09% of all recommendations. A month ago, Strong Buy made up 81.82%, while Buy represented 9.09%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 18 | 18 | 18 | 17 | 16 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 2 | 2 | 1 | 1 | 1 |
Sell | 0 | 0 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.25 | 1.25 | 1.30 | 1.31 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/17/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
4/16/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/11/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/4/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
3/8/2024 | Truist Securities | David S Macdonald | Strong Buy | Strong Buy |
1/15/2024 | SVB Securities | Whit Mayo | Strong Buy | Strong Buy |
11/30/2023 | Stephens | Scott Fidel | Strong Buy | Strong Buy |
10/20/2023 | Mizuho SecuritiesUSA | Ann K Hynes | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.25 |
ABR (Last week) | 1.25 |
# of Recs in ABR | 22 |
Average Target Price | $574.29 |
LT Growth Rate | 13.20% |
Industry | Medical - HMOs |
Industry Rank by ABR | 172 of 252 |
Current Quarter EPS Est: | 6.85 |